# HUMAN ANTITUMOR THERAPY WITH MONOCLONAL ANTIBODIES

> **NIH NIH R01** · STANFORD UNIVERSITY · 1987 · $411,554

## Abstract

In this project we will continue clinical trials of monoclonal antibodies
in human lymphoma.  We will focus on B cell lymphoma using custom-made
anti-idiotype antibodies since this is the area in which the best results
have so far been obtained.  Refinements will be made in patient selection,
antibody development and production and mode of antibody administration in
order to take advantage of the information generated in our earlier trials
and to improve the clinical results.  The clinical and biological
correlates of tumor response will be defined by studies on the antibodies,
the tumor and the host.  Each patient's tumor will be studied for genetic
heterogeneity by immunoglobulin gene rearrangements and by multiple
different anti-idiotype antibodies.  In this way, we hope to continue to
gain insights into the biology of human lymphoid malignancy.

## Key facts

- **NIH application ID:** 3171295
- **Project number:** 5R01CA033399-06
- **Recipient organization:** STANFORD UNIVERSITY
- **SAM.gov UEI:** HJD6G4D6TJY5
- **Principal Investigator:** —
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $411,554
- **Award type:** 5
- **Project period:** 1982-07-01 → 1988-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171295

## Citation

> US National Institutes of Health, RePORTER application 3171295, HUMAN ANTITUMOR THERAPY WITH MONOCLONAL ANTIBODIES (5R01CA033399-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171295. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*